Forogh Soltaninejad

Dr. Forogh Soltaninejad


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2018 in Oman Medical Journal
Verified
Journal Article
Open access
BABabak Amra
Babak Amra
BRBehzad Rahmati
Behzad Rahmati
FSForogh Soltaninejad
Forogh Soltaninejad
AFAwat Feizi
Awat Feizi
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is associated with significant morbidity. We sought to present an updated systematic review of the literature on the accuracy of screening questionnaires for OSA against polysomnography (PSG) as the reference test. Using the main databases (including Medline, Cochrane Database of Systematic Reviews and Scopus) we used a combination of relevant keywords to filter studies published between January 2010 and April 2017. Population-based studies evaluating the accuracy of screening questionnaires for OSA against PSG were included in the review. Thirty-nine studies comprising 18 068 subjects were included. Four screening questionnaires for OSA had been validated in selected studies including the Berlin questionnaire (BQ), STOP-Bang Questionnaire (SBQ), STOP Questionnaire (SQ), and Epworth Sleepiness Scale (ESS). The sensitivity of SBQ in detecting mild (apnea-hypopnea index (AHI) ≥ 5 events/hour) and severe (AHI ≥ 30 events/hour) OSA was higher compared to other screening questionnaires (range from 81.08% to 97.55% and 69.2% to 98.7%, respectively). However, SQ had the highest sensitivity in predicting moderate OSA (AHI ≥ 15 events/hour; range = 41.3% to 100%). SQ and SBQ are reliable tools for screening OSA among sleep clinic patients. Although further validation studies on the screening abilities of these questionnaires on general populations are required.

1 January 2018 in International Journal of Preventive Medicine
Verified
Journal Article
Open access
PDF file
FSForogh Soltaninejad
Forogh Soltaninejad
BABabak Amra
Babak Amra
MJMaedeh Javani
Maedeh Javani
Thomas PenzelThomas Penzel
Thomas Penzel
IFIngo Fietze
Ingo Fietze
ZFZiba Farajzadegan
Ziba Farajzadegan
Background: Obstructive sleep apnea (OSA) is a common disorder characterized by snoring, daytime sleepiness, fatigue, and repeated termination of airflow (apnea). Standard polysomnography (PSG) is diagnostic gold standard for OSA. PSG is expensive and not available everywhere. To identify the best OSA questionnaire for screening in Persian population, we compared Berlin, STOP-BANG, and Epworth Sleepiness Scale (ESS). Methods: In a cross-sectional study conducted on 400 adult patients suspected of OSA in Bamdad Respiratory Research Center, patients completed three questionnaires. For each questionnaire, patients were divided into high risk and low risk. Then, PSG was performed for all patients. According to PSG, patients categorized into without OSA (apnea-hypopnea index [AHI] AHI ≥5), moderate OSA (30> AHI ≥15), and severe OSA (AHI ≥30). Based on questionnaires and PSG results, predictive parameters for screening tests were calculated. Results: There were 234 (58.5%) males and 166 (41.5%) females in study population. Mean age of patients was 49.29 ± 9.75 standard deviation years. There was significant association between age with OSA (P = 0.005) and between body mass index (BMI) and neck circumference, with moderate and severe OSA (P < 0.001). Sensitivities of Berlin, STOP-BANG, and ESS were 86.42%, 81.46%, and 59%, respectively. Specificities of Berlin, STOP-BANG, and ESS were 52.94%, 82.35%, and 76.47%, respectively. Conclusions: This study suggested that Berlin and STOP-BANG are more sensitive and accurate than ESS for OSA screening in Iran.

1 January 2019 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
BABabak Amra
Babak Amra
MPMohsen Pirpiran
Mohsen Pirpiran
FSForogh Soltaninejad
Forogh Soltaninejad
Thomas PenzelThomas Penzel
Thomas Penzel
IFIngo Fietze
Ingo Fietze
CSChristoph Schoebel
Christoph Schoebel
Background: Obstructive sleep apnea (OSA) is a common health issue with serious complications. Regarding the high cost of the polysomnography (PSG), sensitive and inexpensive screening tools are necessary. The objective of this study was to evaluate the predictive value of anthropometric and Mallampati indices for OSA severity in both genders. Materials and Methods: In a cross-sectional study, we evaluated anthropometric data and the Mallampati classification for the patients (n = 205) with age >18 and confirmed OSA in PSG (Apnea–Hypopnea Index [AHI] >5). For predicting the severity of OSA, we applied a decision tree (C5.0) algorithm, with input and target variables considering two models (Model 1: AHI ≥15 with Mallampati >2, age >51 years, and neck circumference [NC] >36 cm and Model 2: AHI ≥30 with condition: gender = female, body mass index (BMI) >35.8, and age >44 years or gender = male, Mallampati ≥2, and abdominal circumference (AC) >112 then AHI ≥30). Results: About 54.1% of the patients were male. Mallampati, age, and NCs are important factors in predicting moderate OSA. The likelihood of moderate OSA severity based on Model 1 was 94.16%. In severe OSA, Mallampati, BMI, age, AC, and gender are more predictive. In Model 2, gender had a significant role. The likelihood of severe OSA based on Model 2 in female patients was 89.98% and in male patients was 90.32%. Comparison of the sensitivity and specificity of both models showed a higher sensitivity of Model 1 (93.5%) and a higher specificity of Model 2 (89.66%). Conclusion: For the prediction of moderate and severe OSA, anthropometric and Mallampati indices are important factors.

13 February 2021 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
BABabak Amra
Babak Amra
MSMehrzad Salmasi
Mehrzad Salmasi
FSForogh Soltaninejad
Forogh Soltaninejad
RSRamin Sami
Ramin Sami
MNMina Nickpour
Mina Nickpour
Charles MorinCharles Morin
Charles Morin

Verified
Journal Article
Open access
PDF file
AVAtefeh Vaezi
Atefeh Vaezi
MSMehrzad Salmasi
Mehrzad Salmasi
FSForogh Soltaninejad
Forogh Soltaninejad
MSMehrdad Salahi
Mehrdad Salahi
SJShaghayegh Haghjooy Javanmard
Shaghayegh Haghjooy Javanmard
BABabak Amra
Babak Amra
Background: Finding effective outpatient treatments to prevent COVID-19 progression and hospitalization is necessary and is helpful in managing limited hospital resources. Repurposing previously existing treatments is highly desirable. In this study, we evaluate the efficacy of Favipiravir in the prevention of hospitalization in symptomatic COVID-19 patients who were not eligible for hospitalization. Methods: This study was a triple-blind randomized controlled trial conducted between 5 December 2020 and 31 March 2021 in three outpatient centers in Isfahan, Iran. Patients in the intervention group received Favipiravir 1600 mg daily for five days, and the control group received a placebo. Our primary outcome was the proportion of hospitalized participants from day 0 to day 28. The outcome was assessed on days 3, 7, 14, 21, and 28 through phone calls. Results: Seventy-seven patients were randomly allocated to Favipiravir and placebo groups. There was no significant difference between groups considering baseline characteristics. During the study period, 10.5% of patients in the Favipiravir group and 5.1% of patients in the placebo group were hospitalized, but there was no significant difference between them (p-value = 0.3). No adverse event was reported in the treatment group. Conclusions: Our study shows that Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in outpatient settings.

10 June 2025 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
FSForogh Soltaninejad
Forogh Soltaninejad
RGReyhaneh Golastaneh
Reyhaneh Golastaneh
PGParham Izadi Ghahfarokhi
Parham Izadi Ghahfarokhi
MSMehrzad Salmasi
Mehrzad Salmasi
BABabak Amra
Babak Amra